- Home
- EBS vs GRAL Comparison
EBS vs GRAL Comparison
Compare EBS & GRAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- GRAL
- Stock Information
- Founded
- EBS 1998
- GRAL 2016
- Country
- EBS United States
- GRAL United States
- Employees
- EBS N/A
- GRAL N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- GRAL
- Sector
- EBS Health Care
- GRAL
- Exchange
- EBS Nasdaq
- GRAL NYSE
- Market Cap
- EBS 393.9M
- GRAL 877.1M
- IPO Year
- EBS 2006
- GRAL N/A
- Fundamental
- Price
- EBS $5.50
- GRAL $37.20
- Analyst Decision
- EBS Strong Buy
- GRAL Buy
- Analyst Count
- EBS 3
- GRAL 3
- Target Price
- EBS $14.33
- GRAL $26.00
- AVG Volume (30 Days)
- EBS 1.2M
- GRAL 1.2M
- Earning Date
- EBS 05-07-2025
- GRAL 05-15-2025
- Dividend Yield
- EBS N/A
- GRAL N/A
- EPS Growth
- EBS N/A
- GRAL N/A
- EPS
- EBS N/A
- GRAL N/A
- Revenue
- EBS $1,043,600,000.00
- GRAL $125,595,000.00
- Revenue This Year
- EBS N/A
- GRAL $24.65
- Revenue Next Year
- EBS $19.88
- GRAL $12.88
- P/E Ratio
- EBS N/A
- GRAL N/A
- Revenue Growth
- EBS N/A
- GRAL 34.90
- 52 Week Low
- EBS $1.82
- GRAL $12.33
- 52 Week High
- EBS $15.10
- GRAL $63.99
- Technical
- Relative Strength Index (RSI)
- EBS 56.40
- GRAL N/A
- Support Level
- EBS $4.13
- GRAL N/A
- Resistance Level
- EBS $4.69
- GRAL N/A
- Average True Range (ATR)
- EBS 0.37
- GRAL 0.00
- MACD
- EBS 0.20
- GRAL 0.00
- Stochastic Oscillator
- EBS 87.80
- GRAL 0.00
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.